Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance

We reported a patient with unresectable hepatocellular carcinoma (HCC) who initially received 15 cycles of atezolizumab plus bevacizumab combination and had best tumor response of partial response, but later experienced disease progression. After subsequent surgical resection, the patient enjoyed lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yulei, Lu, Li-Chun, Guan, Yinghui, Ho, Ming-Chih, Lu, Shan, Spahn, Jessica, Hsu, Chih-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365942/
https://www.ncbi.nlm.nih.gov/pubmed/34399826
http://dx.doi.org/10.1186/s40164-021-00237-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365942/
https://www.ncbi.nlm.nih.gov/pubmed/34399826
http://dx.doi.org/10.1186/s40164-021-00237-y

Ejemplares similares